Phospholipase A2 inhibitors in atherosclerosis: the race is on.
Corson
Marshall A
MA
Division of Cardiology, University of Washington/Harborview Medical Center, Seattle WA 98104, USA. mcorson@u.washington.edu
D000069059:Atorvastatin; D001547:Benzaldehydes / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D017322:Clinical Trials, Phase II as Topic; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010091:Oximes / Q000627:therapeutic use; D054497:Phospholipases A2, Secretory / Q000037:antagonists & inhibitors* / Q000097:blood / Q000145:classification; D011758:Pyrroles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
D000069059:Atorvastatin; D001547:Benzaldehydes; D008078:Cholesterol, LDL; D004791:Enzyme Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010091:Oximes; D054497:Phospholipases A2, Secretory; D011758:Pyrroles; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides